jama semaglutide 📌 Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no 💬 Editor's Note by Dost

For weight management in adults with obesity or overweight with weight-related comorbidities, the medication is titrated up to 2.4 mg weekly

In particular, adenosine receptors (ADOR) A1 and A2B were expressed in both PD plaque-derived cells and tunica-derived cells (Mateus et al., 2018)

Weight Loss Success Stories Real DFW patients, real results from those who tried medications and those who chose surgery

[96] These beneficial effects for patients with potential cardiovascular and renal comorbidities make SGLT1 inhibition as promising as SGLT2 inhibition with the added benefit

Another red flag is unusually low pricing, which may indicate the use of cheap, substandard, or even fake ingredients

Hypoglycemia risk is low, and other possible effects are often mild or absent